These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32270254)

  • 1. Decreased plasma kallikrein activity is associated with reduced kidney function in individuals with type 1 diabetes.
    Härma MA; Dahlström EH; Sandholm N; Forsblom C; Groop PH; Lehto M;
    Diabetologia; 2020 Jul; 63(7):1349-1354. PubMed ID: 32270254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Regulation of natriuresis in diabetic nephropathy].
    Późniak J
    Ann Acad Med Stetin; 2000; 46():241-52. PubMed ID: 11712308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats.
    Tschöpe C; Reinecke A; Seidl U; Yu M; Gavriluk V; Riester U; Gohlke P; Graf K; Bader M; Hilgenfeldt U; Pesquero JB; Ritz E; Unger T
    Am J Physiol; 1999 Dec; 277(6):H2333-40. PubMed ID: 10600853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kallikrein protects against microalbuminuria in experimental type I diabetes.
    Bodin S; Chollet C; Goncalves-Mendes N; Gardes J; Pean F; Heudes D; Bruneval P; Marre M; Alhenc-Gelas F; Bouby N
    Kidney Int; 2009 Aug; 76(4):395-403. PubMed ID: 19516248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary kallikrein excretion in type 1 (insulin-dependent) diabetes mellitus.
    Manto A; Cotroneo P; Porcelli G; D'Errico G; Marra G; Magnani P; Tilli P; Greco AV; Ghirlanda G
    Diabetologia; 1993 May; 36(5):423-7. PubMed ID: 8314446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exogenous kallikrein protects against diabetic nephropathy.
    Liu W; Yang Y; Liu Y; Lu X; Guo S; Wu M; Wang M; Yan L; Wang Q; Zhao X; Tong X; Hu J; Li Y; Hu R; Stanton RC; Zhang Z
    Kidney Int; 2016 Nov; 90(5):1023-1036. PubMed ID: 27546607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes.
    Wadén JM; Dahlström EH; Elonen N; Thorn LM; Wadén J; Sandholm N; Forsblom C; Groop PH;
    Diabetologia; 2019 Jul; 62(7):1268-1274. PubMed ID: 31127314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Estimated Glomerular Filtration Rate and Microvascular Complications in Type II Diabetes Mellitus Patients: A 1-Year Cross-Sectional Study.
    Babaliche P; Nadpara RA; Maldar A
    J Natl Med Assoc; 2019 Feb; 111(1):83-87. PubMed ID: 30032867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX.
    Visser M; van Oerle R; Ten Cate H; Laux V; Mackman N; Heitmeier S; Spronk HMH
    Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):103-111. PubMed ID: 31766871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus.
    Wheelock KM; Cai J; Looker HC; Merchant ML; Nelson RG; Fufaa GD; Weil EJ; Feldman HI; Vasan RS; Kimmel PL; Rovin BH; Mauer M; Klein JB;
    PLoS One; 2017; 12(7):e0180964. PubMed ID: 28700653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes.
    Mohammedi K; Patente TA; Bellili-Muñoz N; Driss F; Monteiro MB; Roussel R; Pavin EJ; Seta N; Fumeron F; Azevedo MJ; Canani LH; Hadjadj S; Marre M; Corrêa-Giannella ML; Velho G
    Diabetologia; 2013 Dec; 56(12):2733-42. PubMed ID: 24057136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assembly and activation of the plasma kallikrein/kinin system: a new interpretation.
    Shariat-Madar Z; Mahdi F; Schmaier AH
    Int Immunopharmacol; 2002 Dec; 2(13-14):1841-9. PubMed ID: 12489798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma kallikrein and diabetic macular edema.
    Feener EP
    Curr Diab Rep; 2010 Aug; 10(4):270-5. PubMed ID: 20535647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes.
    Jaffa AA; Durazo-Arvizu R; Zheng D; Lackland DT; Srikanth S; Garvey WT; Schmaier AH;
    Diabetes; 2003 May; 52(5):1215-21. PubMed ID: 12716755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the renal kallikrein-kinin system in diabetic nephropathy.
    Riad A; Zhuo JL; Schultheiss HP; Tschöpe C
    Curr Opin Nephrol Hypertens; 2007 Jan; 16(1):22-6. PubMed ID: 17143067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive treatment and resistant hypertension in patients with type 1 diabetes by stages of diabetic nephropathy.
    Lithovius R; Harjutsalo V; Forsblom C; Saraheimo M; Groop PH;
    Diabetes Care; 2014; 37(3):709-17. PubMed ID: 24170765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study.
    Petrica L; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Vlad D; Popescu R; Velciov S; Gluhovschi C; Bob F; Ursoniu S; Petrica M; Jianu DC
    J Diabetes Complications; 2015 Mar; 29(2):230-7. PubMed ID: 25511877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus.
    Penno G; Russo E; Garofolo M; Daniele G; Lucchesi D; Giusti L; Sancho Bornez V; Bianchi C; Dardano A; Miccoli R; Del Prato S
    Diabetologia; 2017 Jun; 60(6):1102-1113. PubMed ID: 28357502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes.
    Patente TA; Mohammedi K; Bellili-Muñoz N; Driss F; Sanchez M; Fumeron F; Roussel R; Hadjadj S; Corrêa-Giannella ML; Marre M; Velho G
    Free Radic Biol Med; 2015 Sep; 86():16-24. PubMed ID: 25862415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy.
    Gordin D; Shah H; Shinjo T; St-Louis R; Qi W; Park K; Paniagua SM; Pober DM; Wu IH; Bahnam V; Brissett MJ; Tinsley LJ; Dreyfuss JM; Pan H; Dong Y; Niewczas MA; Amenta P; Sadowski T; Kannt A; Keenan HA; King GL
    Diabetes Care; 2019 Jul; 42(7):1263-1273. PubMed ID: 31076418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.